|
|
 |
|
Viewing report
|
|
|
|
Strategic Perspectives: Pancreatic Cancer - Gemcitabine Combination Therapy is the Future
Datamonitor, Nov 2002, Pages: 125
Pancreatic cancer has a true survival rate below 3%. As the only drug approved for pancreatic cancer, Lilly’s Gemzar (gemcitabine) is firmly established as the gold standard drug therapy. Developmental drugs are producing excellent trial results in combination with gemcitabine, and it appears that it will remain the drug of choice for the disease with others fighting for use in combination. The overall market is likely to grow as more patent protected drugs are used within the indication.Detailed coverage of the patient potential in the seven major markets and analysis of the main unmet needs in the current treatment of the diseaseAnalysis of the therapeutic management of pancreatic cancer in the seven major markets including opinion leader analysis and inputOverview of drugs in Phase III, II, I and preclinical developmentComprehensive analysis of key phase III products, with Datamonitor forecasts of drug revenues to 2010The pancreatic cancer market is currently enjoying slow growth as the uptake of Gemzar continues amongst the prescribing community. However, the market is set for a period of explosive growth as drugs proven to have efficacy in combination with gemcitabine replace cheap generics that are less effective. The launch of new drugs will produce a leap in market value, and this will continue as less toxic drugs are launched.Discover why the market for pancreatic cancer therapeutics is set for explosive growth in the next five yearsUnderstand why survival rates for patients with pancreatic cancer are so low, and target this vital area of unmet needIdentify new pharmacological treatments already in the development pipeline that will improve survivabilityImprove your knowledge of company strategies in the evolving pancreatic cancer market
Customers who bought this item also bought
Pancreatic Cancer - Gold Standard Gemcitabine Waiting to be Challenged
Niche Cancers 2001: Pancreatic Cancer
Stakeholder Opinions: Pancreatic Cancer - Gemzar Dominance will Continue among High Levels of Persistent Unmet Needs
Cancer Pancreatic Cancer
Drugs of Tomorrow: Cancer Overview
Strategic Perspectives 2002: Colorectal Cancer Cost Analysis
Br Malls Participacoes Sa
Br. Holdings Corporation
Drugs of Tommorow 2002: Breast Cancer
Treatment Algorithms 2001 Breast Cancer: Herceptin Falling into Stride
Treatment Algorithms 2001: Lung Cancer
The 2009 Import and Export Market for Butadiene Rubber (BR) in Iran
|
|
|
|
